Illumina, Inc. (NASDAQ:ILMN) Q4 2025 Earnings Call Transcript February 5, 2026 Illumina, Inc. beats earnings expectations.
Researchers reprogrammed bacterial bridge recombinases to edit large genomic regions in mammalian cells, revealing a ...
Rising day and night temperatures are threatening rice, wheat, and maize production by disrupting plant growth, grain filling, and grain quality, putting global food security at risk. Precision ...
1d
Epstein paid for novel genetic testing in apparent effort to explore extending life, new emails show
Convicted sex offender Jeffrey Epstein paid for genetic testing in an apparent bid to harness his own genetic material for ...
All life on Earth shares a common ancestor that lived roughly four billion years ago. This so-called "last universal common ...
Objective To compare the diagnostic accuracy of minipad collected menstrual blood versus clinician collected cervical samples to test for human papillomavirus (HPV) in the detection of cervical ...
A team led by researchers at Baylor College of Medicine and the Duncan Neurological Research Institute (Duncan NRI) at Texas ...
Leveraging human organoid-based mechanistic investigation, researchers reveal how an immunosuppressive drug, antithymocyte ...
Illumina, Inc. ("Illumina" or the "company") today announced its financial results for the fourth quarter and fiscal year 2025. "The Illumina team delivered a strong finish to 2025, marking a return ...
BPC-157 hasn't been approved by the FDA. But that hasn't stopped this buzzy drug from gaining traction – and attention from MAHA.
Revenue of $1.16 billion, up 5% from Q4 2024 (up 4% on a constant currency basis) Ex-China revenue of $1.10 billion, up 8% from Q4 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results